Om

Propanc Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer treatments for patients with pancreatic, ovarian, and colorectal cancers. The company’s current work centers on proenzyme-based therapies designed to address recurring and metastatic disease, with an emphasis on helping control tumor spread and reduce recurrence. Its product pipeline includes lead candidates such as PRP and POP1, which are being developed as long-term therapeutic options for solid tumors. Propanc Biopharma operates in the oncology-focused biotechnology segment of the life sciences market, where it contributes to the development of novel approaches for chronic and advanced cancer care. Headquartered in Camberwell, Australia, the company is positioned as a specialized developer of experimental cancer therapies for use in clinical and preclinical settings.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I PROPANC BIOPHARMA MED ENDAVU: Køb Propanc Biopharma ($PPCB) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Propanc Biopharma, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.